Navigation Links
Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP,by Department of Health and Human Services

reduce mortality from ARS in primates when administered as a single agent hours after radiation exposure without supportive care. This survival benefit was statistically significant, and was generated under GLP conditions. Results were recently published in a peer-reviewed journal. Further, clinical studies support NEUMUNE's attractive safety profile in humans and also show the ability of the compound to significantly increase the production of neutrophils and platelets in healthy volunteers.

"With NEUMUNE's attractive safety and efficacy profile, we are at a loss to explain why HHS would not want to procure this drug candidate for the protection of the American people. It would be more understandable if there were other medical countermeasures as far along in development with a superior profile, but given that HHS has chosen to cancel the solicitation altogether, that is clearly not the case. The ongoing search for a potentially ideal agent may never be realized and at the very least is years away. In the meantime, Americans are left unprotected from what numerous government officials claim is the greatest threat we face as a nation.

"We know that this is not the process Congress intended in overwhelmingly passing the Project BioShield legislation," added Hollis, "and we will make ourselves available over the next several weeks to members of our government who are committed to addressing these shortcomings. More importantly, we will now be tightly focused on moving our three clinical candidates into clinical trials for preventing or treating healthcare acquired infections, diabetes, arthritis and cancer. While this action clearly represents a near-term setback, we are convinced the future for this technology is very bright."

Conference Call: Hollis-Eden will conduct a conference call and live webcast on March 8, 2007 at 11:00 a.m. Eastern (8:00 a.m. Pacific) to discuss today's announcement. The conference call can be accessed by dialing 866-35
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/31/2015)... IRVINE, Calif. , Aug. 31, 2015 /PRNewswire/ ... business and government, where regulations are often strict ... environment is driving a demand for professionals who ... interpret these regulations across a product lifecycle and ... organization. The University of California, Irvine Extension ...
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 2011 Reportlinker.com announces that a new market research ... Global Injectable Drug Delivery Market (2010 - 2015) ... KEY TAKE AWAYS * To ... its various sub-segments with respect to types of systems, ...
... Reportlinker.com announces that a new market research report ... European Markets for Minimally Invasive Spinal Devices ... The European minimally invasive spinal implant ... Rapid growth of the MIS interbody and MIS ...
Cached Medicine Technology:Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 2Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 3Reportlinker Adds European Markets for Minimally Invasive Spinal Devices 2011 2
(Date:9/1/2015)... ... 2015 , ... September is Baby Safety Month, and Lightning Labels ... keep little ones' safety top of mind at all times. , Sponsored by the ... to the JPMA's Baby Safety Zone website, this year's theme is A Room with ...
(Date:9/1/2015)... ... September 01, 2015 , ... The premier online medical ... become a leader in podiatric, surgical and wound care conferences . The ... top national speakers at the podium and across the table during hands-on surgical ...
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, ... release of ten hours of new premium on-demand video Evidence Based Practice ... Athletic Trainers certified before 2014 must complete 50 CEUs before December 31, 2015, ...
(Date:8/31/2015)... , ... September 01, 2015 , ... ... eliminate chronic back pain – once required a long, arduous recovery. However, today’s ... stay, less pain, less blood loss and minimal muscle damage. These advantages of ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly ... Power and Influence by Modern Luxury’s The Atlantan Magazine. , This award ... as Kathy King. Her idea and vision to bring to Atlanta a true ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3
... reliability, improves information flow, facilitates documentation and, compliance, and ... ... outcomes., ... release of an enhanced NaviCare(R) WatchChild(R),solution, following receipt of marketing ...
... Additional Large Transactions in the Pipeline, LIVINGSTON, ... Board: MMGP) announced today that its wholly-owned,subsidiary, Genotec ... generates its sales from the distribution of its ... strategic,partners, has quoted on several large transactions for ...
... systems-based approach that combines comprehensive gene expression profiling with ... researchers to an important genetic marker that can help ... risk and will require more aggressive treatment, a research ... reports in the April 15, 2008, issue of the ...
... Anti-Tumor Activity, DALLAS, April 17 ... results from preclinical studies,ongoing at the prestigious ... monoclonal antibody. The new data, presented by ... Biochemistry,demonstrate that Angiolix has unusually high accumulation ...
... Eisai Corporation of,North America today announces the immediate ... Corporate Communications. In this newly created,position, Mr. Laverty ... Eisai,s corporate communications strategies and activities in the,United ... than 22 years of global corporate,product, policy and ...
... 17 A few years back, the,standard business card had ... side of plain vanilla paper stock, sometimes with,two-color printing to ... on both,sides of a BC in four-color process with a ... for 500 cards. This is a fraction,of what it cost ...
Cached Medicine News:Health News:Hill-Rom's NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care 2Health News:MM2 Group Provides Additional Quotes for New Venture in China 2Health News:Genome analysis reveals new protein associated with breast cancer progression 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 3Health News:Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications 2Health News:Your Business Card is a Powerful Marketing Tool 2
The Equator Convective Warmer incorporates LEVEL 1's unique, patented, temperature control technology to ensure delivery of the desired therapy to the patient....
The QuickVue Advance® G. vaginalis test is an enzyme activity test for use in the detection of Gardnerella vaginalis Proline IminoPeptidase(PIP) activity in vaginal fluid specimens from women su...
The Micro-Temp® II safely and consistently delivers a therapeutic level of localized heat using a pump, connecting hose and localized temperature therapy pad....
The Osom® Bvblue Test detects elevated vaginal fluid sialidase activity, an enzyme produced by bacterial pathogens associated with Bacterial Vaginosis including Gardnerella, Bacteroides, Prevote...
Medicine Products: